Amneal Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.570-0.630 for the period, compared to the consensus estimate of 0.610. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.